Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer ( ts with previously untreated extensive-...)

Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer

ts with previously untreated extensive-stage SCLC, increased survival.

In this study, patients were randomized 1:1 to receive Aranesp 300 mcg or placebo every week (QW) for the first 4 weeks, followed by once every three week (Q3W) dosing (commencing on week 5) for the remainder of the 24-week treatment period. Patients were treated to a target Hb of 13 g/dL, which is higher than indicated by the FDA-approved product label, with dose withholding at 14 g/dL.

Conference Call Information

Amgen will discuss the results of the 145 study during a conference call to review the Company's first quarter financial results with the investment community at 2:00 PM, Pacific Time, Monday, April 23, 2007. Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call, including the question and answer session, is expected to last approximately one hour.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's Web site, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay 72 hours after the event.

About Aranesp

Aranesp was approved by the U.S. Food and Drug Administration (FDA) in September 2001 for the treatment of anemia associated with chronic renal failure (CRF), also known as chronic kidney disease (CKD), for patients on dialysis and patients not on dialysis. In July 2002, the FDA approved weekly dosing of Aranesp for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy, and in March 2006, the FDA approved every-th
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes

Post Your Comments:

(Date:12/16/2009)... Engineered Technologies (HDT), a leader in the development ... for the mechanical development of the Modular Prosthetic ... technology that will give patients improved, dexterous control ... sense of touch. ,, As part of ... Prosthetics 2009 (RP2009) project, the MPL overcomes the ...

(Date:12/16/2009)... -- Accuray Incorporated (Nasdaq: ARAY ), a global ... its president and chief executive officer, Euan S. Thomson, ... J.P. Morgan Healthcare Conference in San Francisco on Wednesday, ... ,, A live webcast of each presentation will ... the Company,s Web site at http://www.accuray.com . ...

(Date:12/16/2009)... 16 DATATRAK International, Inc. (OTCQX: ... on global eClinical solutions for the clinical ... its version 9.0 eClinical Software. This ... product and service delivery and introduces two ... offering: the DATATRAK Learning Center(TM) and the ...

[0] HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program [0] Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference [0] DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)

... Response Rate and 100% Disease Control Rate Observed in ... Patients with Medullary Thyroid Cancer, CHICAGO, June ... from an ongoing phase 1 clinical trial of,XL184, a novel small ... The maximum tolerated dose (MTD) for,XL184 has been determined to be ...

... Research Subsidiary HealthCore Presents Data on, Contributing Factors and ... ... INDIANAPOLIS, June 1 HealthCore today,presented a study ... treatment guidelines for newly diagnosed breast,cancer patients at the ...

Other Medicine Technology:Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2 Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3 Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4 Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5 Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6 Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women 2 Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women 3

Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women

(Date:12/17/2009)... StaffKnex, developers of web-based nurse scheduling and employee communication ... to deliver its software solution to all Lifespace Communities ... ... Cleveland, OH (PRWEB) December 17, 2009 -- StaffKnex ( ... communication software, recently announced it was selected by Lifespace ...

(Date:12/17/2009)... Baptist with on-going Healthcare Cost/Risk Analysis reports, activity measures and ... as it translates toward reduced claim costs and positive return ... , ... Jacksonville, FL (PRWEB) December ... management company specializing in clinical/claims based cost risk analysis along ...

(Date:12/16/2009)... Dec. 17 Health care sector revenue ... trillion, up from $1.66 trillion in 2007, according ... This sector is classified under the North American ... http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) ,, These figures come from ... and Social Assistance , a series of tables ...

(Date:12/16/2009)... year in the United States, 160,000 cases of colorectal ... disease, making it the second leading cause of death ... researchers and clinicians fervently look for causes and cures ... producing more and more promising results Dr. Sanford ... Case Western Reserve University School of Medicine and oncologist ...

(Date:12/16/2009)... For wounded U.S. servicemen and women recovering at ... holidays can be a particularly difficult time. Wounded ... than ever on the healing power of connecting with ... got easier for Walter Reed patients as Verizon Wireless ... hundreds of minutes of holiday talk time for 2,500 ...

Breaking Medicine News(10 mins):Health News:Lifespace Communities Selects StaffKnex Software for Nurse Scheduling and Employee Communications 2 Health News:Lifespace Communities Selects StaffKnex Software for Nurse Scheduling and Employee Communications 3 Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2 Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2 Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3 Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2 Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3 Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2

[0] Lifespace Communities Selects StaffKnex Software for Nurse Scheduling and Employee Communications [0] Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services [1] Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 [1] New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer'[0] Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital

... Palomar Medical Technologies, Inc. (Nasdaq: PMTI ... for cosmetic treatments, announced today that Palomar won two ... on May 6 and 13, 2009. The opposition ... 0 806 913, respectively, which correspond to U.S. Patent ...

... Announces Partnership to Provide New Yorkers with Free HIV/AIDS TestingNEW ... today announced that The Duane Reade Charitable Foundation has doubled ... a Premier-level sponsor of AIDS Walk New York (AWNY). ... fifty other AIDS service organizations in the New York tri-state ...

... Research on Antioxidant-Enhanced SuncareKENILWORTH, N.J., May 14 ... SGP ), introduces COPPERTONE (R) , NutraShield ... new line of sunscreens enriched with antioxidants to ... free radicals created by UV exposure. (Photo: ...

... All New 4th Edition NEW YORK, May 14 ... Spinal Network: The Total Wheelchair Resource Book , ... is now available.This 400-page guide provides information on health, ... and sexuality, fertility and parenting, adaptive technology, spinal cord ...

... legislative action in the best interests of the ... bank accounts?COLLEYVILLE, Texas, May 14 Our leading ... marketed e-cigarettes. This parade is lead by the ... health conscious senator, who has taken well over ...

... Healthcare has launched the free online board, MedicalMissions.org ( http://www.medicalmissions.org ... around the world. The new website is designed for charitable ... volunteer interests and needs. , ... ...

Other Medicine News:Health News:Palomar Wins Two European Hair Removal Patent Opposition Hearings 2 Health News:Palomar Wins Two European Hair Removal Patent Opposition Hearings 3 Health News:Palomar Wins Two European Hair Removal Patent Opposition Hearings 4 Health News:Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York 2 Health News:Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair 2 Health News:Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair 3 Health News:Spinal Network: The Total Wheelchair Resource Book 2 Health News:Proposed E-Cigarette Ban Pushed in the Name of America's Health Actually a Backdoor Boost to Pharmaceutical Companies 2 Health News:Free Medical Mission 'Job Board' Launched 2 Health News:Free Medical Mission 'Job Board' Launched 3

Palomar Wins Two European Hair Removal Patent Opposition Hearings Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair Spinal Network: The Total Wheelchair Resource Book Proposed E-Cigarette Ban Pushed in the Name of America's Health Actually a Backdoor Boost to Pharmaceutical Companies Free Medical Mission 'Job Board' Launched

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

Medicine Products:

Respiratory Syncytial Virus Antibody, IgG Reserpine, Serum or Plasma Reptilase Time with Reflex to Reptilase Time 1:1 Mix Renal Pelvis Washing/Brushing for Cytology

( ts with previously untreated extensive-...)Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer,Health